Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients

Ramalingam Arumugam, Humberto E. Soriano, Ann Scheimann, Barbara S. Reid, G. S. Gopalakrishna, Omar Barakat, Claire F. Ozaki, Patrick R. Wood

Research output: Contribution to journalArticle

Abstract

Intravenous administration of cyclosporine (Sandimmune®) to rapidly and effectively achieve therapeutic serum levels in transplant recipients has been the treatment standard in many transplantation centers. With the development of microemulsion cyclosporine (Neoral®), that standard is changing. Neoral has greater bioavailability than the oral form of Sandimmune and, consequently, can be more efficacious and cost-effective. To test this hypothesis, we undertook a retrospective study of Sandimmune and Neoral in the treatment of 66 children who underwent uncomplicated orthotopic liver transplantation in the Texas Medical Center between April 1991 and December 1997. Both forms of cyclosporine were evaluated in terms of in-patient treatment cost, recuperative time in the intensive care unit and duration of hospitalization. Twenty-two patients were treated orally with Neoral, and 44 patients were treated intravenously with Sandimmune for a mean time of 14 d. Once the blood concentration of Sandimmune reached a steady state, as confirmed by daily measurements of the trough level, the patients in the Sandimmune group were converted to oral cyclosporine. None of the 22 patients treated with Neoral required intravenous treatment. The mean time spent in the intensive care unit was 4 d for the Neoral group and 5.5 d for the Sandimmune group. The mean duration of hospitalization from the date of transplantation to discharge was 12 d for the Neoral group and 20 d for the Sandimmune group (p <0.001). Based on these results, we determined that the overall cost per patient in the Neoral group was $3598 less than that per patient in the Sandimmune group.

Original languageEnglish (US)
Pages (from-to)588-592
Number of pages5
JournalClinical Transplantation
Volume12
Issue number6
StatePublished - Dec 1998
Externally publishedYes

Fingerprint

Immunosuppressive Agents
Cyclosporine
Hospitalization
Pediatrics
Liver
Therapeutics
Transplant Recipients
Intensive Care Units
Transplantation
Costs and Cost Analysis

Keywords

  • Cost-effective treatment
  • Cyclosporine
  • Hospitalization cost
  • Length of hospital stay
  • Neoral
  • Pediatric liver transplantation
  • Sandimmune

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Arumugam, R., Soriano, H. E., Scheimann, A., Reid, B. S., Gopalakrishna, G. S., Barakat, O., ... Wood, P. R. (1998). Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients. Clinical Transplantation, 12(6), 588-592.

Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients. / Arumugam, Ramalingam; Soriano, Humberto E.; Scheimann, Ann; Reid, Barbara S.; Gopalakrishna, G. S.; Barakat, Omar; Ozaki, Claire F.; Wood, Patrick R.

In: Clinical Transplantation, Vol. 12, No. 6, 12.1998, p. 588-592.

Research output: Contribution to journalArticle

Arumugam, R, Soriano, HE, Scheimann, A, Reid, BS, Gopalakrishna, GS, Barakat, O, Ozaki, CF & Wood, PR 1998, 'Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients', Clinical Transplantation, vol. 12, no. 6, pp. 588-592.
Arumugam, Ramalingam ; Soriano, Humberto E. ; Scheimann, Ann ; Reid, Barbara S. ; Gopalakrishna, G. S. ; Barakat, Omar ; Ozaki, Claire F. ; Wood, Patrick R. / Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients. In: Clinical Transplantation. 1998 ; Vol. 12, No. 6. pp. 588-592.
@article{93d076e7b71a4932aa3bed49d0fbde57,
title = "Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients",
abstract = "Intravenous administration of cyclosporine (Sandimmune{\circledR}) to rapidly and effectively achieve therapeutic serum levels in transplant recipients has been the treatment standard in many transplantation centers. With the development of microemulsion cyclosporine (Neoral{\circledR}), that standard is changing. Neoral has greater bioavailability than the oral form of Sandimmune and, consequently, can be more efficacious and cost-effective. To test this hypothesis, we undertook a retrospective study of Sandimmune and Neoral in the treatment of 66 children who underwent uncomplicated orthotopic liver transplantation in the Texas Medical Center between April 1991 and December 1997. Both forms of cyclosporine were evaluated in terms of in-patient treatment cost, recuperative time in the intensive care unit and duration of hospitalization. Twenty-two patients were treated orally with Neoral, and 44 patients were treated intravenously with Sandimmune for a mean time of 14 d. Once the blood concentration of Sandimmune reached a steady state, as confirmed by daily measurements of the trough level, the patients in the Sandimmune group were converted to oral cyclosporine. None of the 22 patients treated with Neoral required intravenous treatment. The mean time spent in the intensive care unit was 4 d for the Neoral group and 5.5 d for the Sandimmune group. The mean duration of hospitalization from the date of transplantation to discharge was 12 d for the Neoral group and 20 d for the Sandimmune group (p <0.001). Based on these results, we determined that the overall cost per patient in the Neoral group was $3598 less than that per patient in the Sandimmune group.",
keywords = "Cost-effective treatment, Cyclosporine, Hospitalization cost, Length of hospital stay, Neoral, Pediatric liver transplantation, Sandimmune",
author = "Ramalingam Arumugam and Soriano, {Humberto E.} and Ann Scheimann and Reid, {Barbara S.} and Gopalakrishna, {G. S.} and Omar Barakat and Ozaki, {Claire F.} and Wood, {Patrick R.}",
year = "1998",
month = "12",
language = "English (US)",
volume = "12",
pages = "588--592",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients

AU - Arumugam, Ramalingam

AU - Soriano, Humberto E.

AU - Scheimann, Ann

AU - Reid, Barbara S.

AU - Gopalakrishna, G. S.

AU - Barakat, Omar

AU - Ozaki, Claire F.

AU - Wood, Patrick R.

PY - 1998/12

Y1 - 1998/12

N2 - Intravenous administration of cyclosporine (Sandimmune®) to rapidly and effectively achieve therapeutic serum levels in transplant recipients has been the treatment standard in many transplantation centers. With the development of microemulsion cyclosporine (Neoral®), that standard is changing. Neoral has greater bioavailability than the oral form of Sandimmune and, consequently, can be more efficacious and cost-effective. To test this hypothesis, we undertook a retrospective study of Sandimmune and Neoral in the treatment of 66 children who underwent uncomplicated orthotopic liver transplantation in the Texas Medical Center between April 1991 and December 1997. Both forms of cyclosporine were evaluated in terms of in-patient treatment cost, recuperative time in the intensive care unit and duration of hospitalization. Twenty-two patients were treated orally with Neoral, and 44 patients were treated intravenously with Sandimmune for a mean time of 14 d. Once the blood concentration of Sandimmune reached a steady state, as confirmed by daily measurements of the trough level, the patients in the Sandimmune group were converted to oral cyclosporine. None of the 22 patients treated with Neoral required intravenous treatment. The mean time spent in the intensive care unit was 4 d for the Neoral group and 5.5 d for the Sandimmune group. The mean duration of hospitalization from the date of transplantation to discharge was 12 d for the Neoral group and 20 d for the Sandimmune group (p <0.001). Based on these results, we determined that the overall cost per patient in the Neoral group was $3598 less than that per patient in the Sandimmune group.

AB - Intravenous administration of cyclosporine (Sandimmune®) to rapidly and effectively achieve therapeutic serum levels in transplant recipients has been the treatment standard in many transplantation centers. With the development of microemulsion cyclosporine (Neoral®), that standard is changing. Neoral has greater bioavailability than the oral form of Sandimmune and, consequently, can be more efficacious and cost-effective. To test this hypothesis, we undertook a retrospective study of Sandimmune and Neoral in the treatment of 66 children who underwent uncomplicated orthotopic liver transplantation in the Texas Medical Center between April 1991 and December 1997. Both forms of cyclosporine were evaluated in terms of in-patient treatment cost, recuperative time in the intensive care unit and duration of hospitalization. Twenty-two patients were treated orally with Neoral, and 44 patients were treated intravenously with Sandimmune for a mean time of 14 d. Once the blood concentration of Sandimmune reached a steady state, as confirmed by daily measurements of the trough level, the patients in the Sandimmune group were converted to oral cyclosporine. None of the 22 patients treated with Neoral required intravenous treatment. The mean time spent in the intensive care unit was 4 d for the Neoral group and 5.5 d for the Sandimmune group. The mean duration of hospitalization from the date of transplantation to discharge was 12 d for the Neoral group and 20 d for the Sandimmune group (p <0.001). Based on these results, we determined that the overall cost per patient in the Neoral group was $3598 less than that per patient in the Sandimmune group.

KW - Cost-effective treatment

KW - Cyclosporine

KW - Hospitalization cost

KW - Length of hospital stay

KW - Neoral

KW - Pediatric liver transplantation

KW - Sandimmune

UR - http://www.scopus.com/inward/record.url?scp=0031722789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031722789&partnerID=8YFLogxK

M3 - Article

C2 - 9850457

AN - SCOPUS:0031722789

VL - 12

SP - 588

EP - 592

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -